<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In the era of eculizumab, identifying patients with <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> who may benefit from allogeneic stem cell transplantation is challenging </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: We describe the characteristics and overall survival of 211 patients transplanted for <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> in 83 EBMT centers from 1978 to 2007 </plain></SENT>
<SENT sid="2" pm="."><plain>Next, we conducted a comparison with a cohort of 402 non-transplanted patients with <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> diagnosed between 1950 and 2005 in 92 French centers </plain></SENT>
<SENT sid="3" pm="."><plain>We compared the occurrence of complications (i.e. <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>) using either an individual or a stratum-matching procedure </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After a median follow-up of 5 years, the 5-year overall survival rate ± standard error (%) was 68 ± 3 in the transplanted group (54 ± 7 in the case of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, 69 ± 5 in the case of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> without <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and 86 ± 6 in the case of recurrent <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> without <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>Only <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> as the indication for transplantation was associated with worse outcome (P=0.03) </plain></SENT>
<SENT sid="6" pm="."><plain>We identified 24 pairs of transplanted and non-transplanted patients with <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> for the matched comparison, with worse overall survival for the transplanted patients (hazard ratio=10.0; 95% confidence interval, 1.3-78.1; P=0.007) </plain></SENT>
<SENT sid="7" pm="."><plain>This was confirmed by the global matching procedure (P=0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>As regards <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> without <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, 30 pairs were identified for the matched comparison </plain></SENT>
<SENT sid="9" pm="."><plain>It was not observed that transplanted patients had a significantly worse overall survival (hazard ratio=4.0; 95% confidence interval, 0.9-18.9; P=0.06) </plain></SENT>
<SENT sid="10" pm="."><plain>A global matching procedure was not feasible </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Allogeneic stem cell transplantation is probably not a suitable treatment option for life-threatening <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> </plain></SENT>
</text></document>